Oligonucleotide Synthesis Market worth $32.72 billion by 2031
The report "Oligonucleotide Synthesis Market by Offering [Synthesis Products (Consumables, Equipment), Synthesized Oligos (DNA, RNA), Oligo-based Drugs (ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031", is projected to grow from USD 14.64 billion in 2026 and to reach USD 32.72 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 17.4% during the forecast period.
Browse 600 market data Tables and 80 Figures spread through 460 Pages and in-depth TOC on "Oligonucleotide Synthesis Market by Offering [Synthesis Products (Consumables, Equipment), Synthesized Oligos (DNA, RNA), Oligo-based Drugs (ASO, siRNA), Therapy Area [Rare Diseases, Neurology, Oncology], Competition - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html
The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing use of oligonucleotides in therapeutics and diagnostics, rapid technological advances in oligonucleotide synthesis, and favorable government investments in life sciences research and synthetic biology. The growing focus on precision and personalized medicine also fuels market growth. Emerging regions are creating new opportunities for market players as R&D investments in these economies are on the rise.
By type, the antisense oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.
By type, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2025, the ASOs (antisense oligonucleotide-based drugs) segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. They have seen rapid clinical and commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst and investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines.
In 2025, the hospitals segment accounted for the largest share of the oligonucleotide-based drugs market.
By end user, the oligonucleotide-based drugs market includes hospitals, specialty clinics, home care settings, and other end users. In 2025, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to rising demand for oligonucleotide-based drugs for rare and neurological diseases, primarily driven by an increasing target patient population. This segment's significant share reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious and chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America accounted for the largest share of the oligonucleotide synthesis market, owing to the presence of strong regional players with advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals under supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers to scale up production are also expected to be growth drivers for this regional segment.
Leading players in the oligonucleotide synthesis products and oligonucleotide synthesis market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others.
Some of the leading players in the oligonucleotide-based drugs include Alnylam Pharmaceuticals, Inc. (US), Biogen (US), Sarepta Therapeutics, Inc. (US), and Novartis AG (Switzerland), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
